Review





Similar Products

par1 protein  (Molecular Dynamics Inc)
86
Molecular Dynamics Inc par1 protein
Par1 Protein, supplied by Molecular Dynamics Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par1+protein/par1+protein/10__1016_slash_j__bbrep__2025__102430-172-15-0
Average 86 stars, based on 1 article reviews
par1 protein - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier
par1 g protein complexes bac  (Thermo Fisher)
96
Thermo Fisher par1 g protein complexes bac
Par1 G Protein Complexes Bac, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par1+protein/Bacitracin/pm38997424-152-4-11
Average 96 stars, based on 1 article reviews
par1 g protein complexes bac - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier
fiia-activated par1-positive (the antibody detects fragments of activated par1-cleaved-ser42 protein)  (Millipore)
90
Millipore fiia-activated par1-positive (the antibody detects fragments of activated par1-cleaved-ser42 protein)
Pro-inflammatory immune cell function in FDAF—Indications for PAR1 activation via thrombin. ( A ) Increased plasma levels of pro-inflammatory mediators, namely tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), were seen in patients with FDAF. ( B ) Phenotyping via flow cytometry of peripheral blood mononuclear cells (PBMCs) revealed a higher percentage (% of total PBMCs) of circulating pro-inflammatory cells that <t>possess</t> <t>thrombin-activated</t> (cleaved) PAR1 (TNF-α + or IL-6 + cleaved PAR1 + ) in patients with FDAF. The antibody detects fragments of activated PAR1-cleaved-Ser42 protein. Cytokines TNF-α and IL-6 were visualized via intracellular staining of permeabilized cells. ( C – E ) Evaluation of different immune cell subsets expressing PAR1 via flow cytometry. Antigen-presenting cells (APCs; HLA-DR + ) ( C ), non-T cells (CD3 − ) ( D ), and lymphocytes ( E ). Left panel: percentage of a specified immune cell population expressing PAR1. Right panel: Increased mean fluorescence intensity (MFI) of PAR1. Extracellular (surface) PAR1 expression (=PAR1 that is accessible for activation via <t>FIIa)</t> was detected via staining of unpermeabilized PBMCs with a PAR1 antibody. Patients with FDAF ( n = 80) were compared to controls (patients with chronic cardiovascular diseases but without AF) ( n = 20). Results are expressed as single values, median, and p -values.
Fiia Activated Par1 Positive (The Antibody Detects Fragments Of Activated Par1 Cleaved Ser42 Protein), supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par1+protein/par1+ap++sfllrn/pmc11012942-216-3-13
Average 90 stars, based on 1 article reviews
fiia-activated par1-positive (the antibody detects fragments of activated par1-cleaved-ser42 protein) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
recombinant human par1  (Sino Biological)
91
Sino Biological recombinant human par1
Pro-inflammatory immune cell function in FDAF—Indications for PAR1 activation via thrombin. ( A ) Increased plasma levels of pro-inflammatory mediators, namely tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), were seen in patients with FDAF. ( B ) Phenotyping via flow cytometry of peripheral blood mononuclear cells (PBMCs) revealed a higher percentage (% of total PBMCs) of circulating pro-inflammatory cells that <t>possess</t> <t>thrombin-activated</t> (cleaved) PAR1 (TNF-α + or IL-6 + cleaved PAR1 + ) in patients with FDAF. The antibody detects fragments of activated PAR1-cleaved-Ser42 protein. Cytokines TNF-α and IL-6 were visualized via intracellular staining of permeabilized cells. ( C – E ) Evaluation of different immune cell subsets expressing PAR1 via flow cytometry. Antigen-presenting cells (APCs; HLA-DR + ) ( C ), non-T cells (CD3 − ) ( D ), and lymphocytes ( E ). Left panel: percentage of a specified immune cell population expressing PAR1. Right panel: Increased mean fluorescence intensity (MFI) of PAR1. Extracellular (surface) PAR1 expression (=PAR1 that is accessible for activation via <t>FIIa)</t> was detected via staining of unpermeabilized PBMCs with a PAR1 antibody. Patients with FDAF ( n = 80) were compared to controls (patients with chronic cardiovascular diseases but without AF) ( n = 20). Results are expressed as single values, median, and p -values.
Recombinant Human Par1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par1+protein/Human+F2R+%2F+Coagulation+factor+II+receptor+%2F+Thrombin+Receptor+Protein/pm37667257-87-3-12
Average 91 stars, based on 1 article reviews
recombinant human par1 - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier
human ace2 receptor protein constructs  (R&D Systems)
90
R&D Systems human ace2 receptor protein constructs
Pro-inflammatory immune cell function in FDAF—Indications for PAR1 activation via thrombin. ( A ) Increased plasma levels of pro-inflammatory mediators, namely tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), were seen in patients with FDAF. ( B ) Phenotyping via flow cytometry of peripheral blood mononuclear cells (PBMCs) revealed a higher percentage (% of total PBMCs) of circulating pro-inflammatory cells that <t>possess</t> <t>thrombin-activated</t> (cleaved) PAR1 (TNF-α + or IL-6 + cleaved PAR1 + ) in patients with FDAF. The antibody detects fragments of activated PAR1-cleaved-Ser42 protein. Cytokines TNF-α and IL-6 were visualized via intracellular staining of permeabilized cells. ( C – E ) Evaluation of different immune cell subsets expressing PAR1 via flow cytometry. Antigen-presenting cells (APCs; HLA-DR + ) ( C ), non-T cells (CD3 − ) ( D ), and lymphocytes ( E ). Left panel: percentage of a specified immune cell population expressing PAR1. Right panel: Increased mean fluorescence intensity (MFI) of PAR1. Extracellular (surface) PAR1 expression (=PAR1 that is accessible for activation via <t>FIIa)</t> was detected via staining of unpermeabilized PBMCs with a PAR1 antibody. Patients with FDAF ( n = 80) were compared to controls (patients with chronic cardiovascular diseases but without AF) ( n = 20). Results are expressed as single values, median, and p -values.
Human Ace2 Receptor Protein Constructs, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par1+protein/Recombinant+Human+PAR1%2FThrombin+Receptor+Protein/pm37446012-196-4-12
Average 90 stars, based on 1 article reviews
human ace2 receptor protein constructs - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
fiia-activated par1-positive antibody detects fragments activated par1-cleaved-ser42 protein  (Millipore)
90
Millipore fiia-activated par1-positive antibody detects fragments activated par1-cleaved-ser42 protein
Pro-inflammatory immune cell function in FDAF—Indications for PAR1 activation via thrombin. ( A ) Increased plasma levels of pro-inflammatory mediators, namely tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), were seen in patients with FDAF. ( B ) Phenotyping via flow cytometry of peripheral blood mononuclear cells (PBMCs) revealed a higher percentage (% of total PBMCs) of circulating pro-inflammatory cells that <t>possess</t> <t>thrombin-activated</t> (cleaved) PAR1 (TNF-α + or IL-6 + cleaved PAR1 + ) in patients with FDAF. The antibody detects fragments of activated PAR1-cleaved-Ser42 protein. Cytokines TNF-α and IL-6 were visualized via intracellular staining of permeabilized cells. ( C – E ) Evaluation of different immune cell subsets expressing PAR1 via flow cytometry. Antigen-presenting cells (APCs; HLA-DR + ) ( C ), non-T cells (CD3 − ) ( D ), and lymphocytes ( E ). Left panel: percentage of a specified immune cell population expressing PAR1. Right panel: Increased mean fluorescence intensity (MFI) of PAR1. Extracellular (surface) PAR1 expression (=PAR1 that is accessible for activation via <t>FIIa)</t> was detected via staining of unpermeabilized PBMCs with a PAR1 antibody. Patients with FDAF ( n = 80) were compared to controls (patients with chronic cardiovascular diseases but without AF) ( n = 20). Results are expressed as single values, median, and p -values.
Fiia Activated Par1 Positive Antibody Detects Fragments Activated Par1 Cleaved Ser42 Protein, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par1+protein/anti+cpar1++cleaved+ser+42/pm36611934-78-3-13
Average 90 stars, based on 1 article reviews
fiia-activated par1-positive antibody detects fragments activated par1-cleaved-ser42 protein - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
par1 protein  (Federation of European Neuroscience Societies)
90
Federation of European Neuroscience Societies par1 protein
Pro-inflammatory immune cell function in FDAF—Indications for PAR1 activation via thrombin. ( A ) Increased plasma levels of pro-inflammatory mediators, namely tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), were seen in patients with FDAF. ( B ) Phenotyping via flow cytometry of peripheral blood mononuclear cells (PBMCs) revealed a higher percentage (% of total PBMCs) of circulating pro-inflammatory cells that <t>possess</t> <t>thrombin-activated</t> (cleaved) PAR1 (TNF-α + or IL-6 + cleaved PAR1 + ) in patients with FDAF. The antibody detects fragments of activated PAR1-cleaved-Ser42 protein. Cytokines TNF-α and IL-6 were visualized via intracellular staining of permeabilized cells. ( C – E ) Evaluation of different immune cell subsets expressing PAR1 via flow cytometry. Antigen-presenting cells (APCs; HLA-DR + ) ( C ), non-T cells (CD3 − ) ( D ), and lymphocytes ( E ). Left panel: percentage of a specified immune cell population expressing PAR1. Right panel: Increased mean fluorescence intensity (MFI) of PAR1. Extracellular (surface) PAR1 expression (=PAR1 that is accessible for activation via <t>FIIa)</t> was detected via staining of unpermeabilized PBMCs with a PAR1 antibody. Patients with FDAF ( n = 80) were compared to controls (patients with chronic cardiovascular diseases but without AF) ( n = 20). Results are expressed as single values, median, and p -values.
Par1 Protein, supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par1+protein/par1+protein/pm33448150-96-48-34
Average 90 stars, based on 1 article reviews
par1 protein - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
human receptor proteins  (R&D Systems)
90
R&D Systems human receptor proteins
Pro-inflammatory immune cell function in FDAF—Indications for PAR1 activation via thrombin. ( A ) Increased plasma levels of pro-inflammatory mediators, namely tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), were seen in patients with FDAF. ( B ) Phenotyping via flow cytometry of peripheral blood mononuclear cells (PBMCs) revealed a higher percentage (% of total PBMCs) of circulating pro-inflammatory cells that <t>possess</t> <t>thrombin-activated</t> (cleaved) PAR1 (TNF-α + or IL-6 + cleaved PAR1 + ) in patients with FDAF. The antibody detects fragments of activated PAR1-cleaved-Ser42 protein. Cytokines TNF-α and IL-6 were visualized via intracellular staining of permeabilized cells. ( C – E ) Evaluation of different immune cell subsets expressing PAR1 via flow cytometry. Antigen-presenting cells (APCs; HLA-DR + ) ( C ), non-T cells (CD3 − ) ( D ), and lymphocytes ( E ). Left panel: percentage of a specified immune cell population expressing PAR1. Right panel: Increased mean fluorescence intensity (MFI) of PAR1. Extracellular (surface) PAR1 expression (=PAR1 that is accessible for activation via <t>FIIa)</t> was detected via staining of unpermeabilized PBMCs with a PAR1 antibody. Patients with FDAF ( n = 80) were compared to controls (patients with chronic cardiovascular diseases but without AF) ( n = 20). Results are expressed as single values, median, and p -values.
Human Receptor Proteins, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/par1+protein/Recombinant+Human+PAR1%2FThrombin+Receptor+Protein/pmc08409756-63-11-24
Average 90 stars, based on 1 article reviews
human receptor proteins - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Pro-inflammatory immune cell function in FDAF—Indications for PAR1 activation via thrombin. ( A ) Increased plasma levels of pro-inflammatory mediators, namely tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), were seen in patients with FDAF. ( B ) Phenotyping via flow cytometry of peripheral blood mononuclear cells (PBMCs) revealed a higher percentage (% of total PBMCs) of circulating pro-inflammatory cells that possess thrombin-activated (cleaved) PAR1 (TNF-α + or IL-6 + cleaved PAR1 + ) in patients with FDAF. The antibody detects fragments of activated PAR1-cleaved-Ser42 protein. Cytokines TNF-α and IL-6 were visualized via intracellular staining of permeabilized cells. ( C – E ) Evaluation of different immune cell subsets expressing PAR1 via flow cytometry. Antigen-presenting cells (APCs; HLA-DR + ) ( C ), non-T cells (CD3 − ) ( D ), and lymphocytes ( E ). Left panel: percentage of a specified immune cell population expressing PAR1. Right panel: Increased mean fluorescence intensity (MFI) of PAR1. Extracellular (surface) PAR1 expression (=PAR1 that is accessible for activation via FIIa) was detected via staining of unpermeabilized PBMCs with a PAR1 antibody. Patients with FDAF ( n = 80) were compared to controls (patients with chronic cardiovascular diseases but without AF) ( n = 20). Results are expressed as single values, median, and p -values.

Journal: International Journal of Molecular Sciences

Article Title: Characterization of Biomarkers of Thrombo-Inflammation in Patients with First-Diagnosed Atrial Fibrillation

doi: 10.3390/ijms25074109

Figure Lengend Snippet: Pro-inflammatory immune cell function in FDAF—Indications for PAR1 activation via thrombin. ( A ) Increased plasma levels of pro-inflammatory mediators, namely tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), were seen in patients with FDAF. ( B ) Phenotyping via flow cytometry of peripheral blood mononuclear cells (PBMCs) revealed a higher percentage (% of total PBMCs) of circulating pro-inflammatory cells that possess thrombin-activated (cleaved) PAR1 (TNF-α + or IL-6 + cleaved PAR1 + ) in patients with FDAF. The antibody detects fragments of activated PAR1-cleaved-Ser42 protein. Cytokines TNF-α and IL-6 were visualized via intracellular staining of permeabilized cells. ( C – E ) Evaluation of different immune cell subsets expressing PAR1 via flow cytometry. Antigen-presenting cells (APCs; HLA-DR + ) ( C ), non-T cells (CD3 − ) ( D ), and lymphocytes ( E ). Left panel: percentage of a specified immune cell population expressing PAR1. Right panel: Increased mean fluorescence intensity (MFI) of PAR1. Extracellular (surface) PAR1 expression (=PAR1 that is accessible for activation via FIIa) was detected via staining of unpermeabilized PBMCs with a PAR1 antibody. Patients with FDAF ( n = 80) were compared to controls (patients with chronic cardiovascular diseases but without AF) ( n = 20). Results are expressed as single values, median, and p -values.

Article Snippet: The percentage of FIIa-activated PAR1-positive (the antibody detects fragments of activated PAR1-cleaved-Ser42 protein) (Sigma-Aldrich, St. Louis, MO, USA) (visualized with goat anti-rabbit IgG Alexa 405; Thermo Fisher Scientific, Waltham, MA, USA) circulating PBMCs was measured by using flow cytometry with FACSCaliburTM and CellQuest software 5.1 (both from Becton, Dickinson and Company, Franklin Lakes, NJ, USA).

Techniques: Cell Function Assay, Activation Assay, Flow Cytometry, Staining, Expressing, Fluorescence